{
    "clinical_study": {
        "@rank": "164913", 
        "acronym": "TRIPLE10", 
        "arm_group": {
            "arm_group_label": "CHF5993 pMDI", 
            "arm_group_type": "Experimental", 
            "description": "CHF 5993 pMDI (Beclometasone/Formoterol/Glycopyrrolate 100/6/25 mcg) 4 inhalations"
        }, 
        "brief_summary": {
            "textblock": "The study is performed to characterize the pharmacokinetics of glycopyrrolate bromide after\n      single administration of CHF 5993 pressurised Metered Dose Inhaler (pMDI) in subjects with\n      different level of renal impairment in comparison with matching healthy volunteers.\n      Moreover, the safety and tolerability of the study drug will be also evaluated."
        }, 
        "brief_title": "A Study to Investigate the Pharmacokinetics, Safety and Tolerability of CHF 5993 pMDI in Subjects With Renal Impairment.", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Obstructive Pulmonary Disease (COPD)", 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Renal Insufficiency", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy volunteers and\n\n          -  Subjects with mild, moderate and severe renal impairment\n\n        Exclusion Criteria:\n\n          -  pregnant or lactating women\n\n          -  positive HIV and hepatitis serology\n\n          -  history of drug abuse\n\n          -  history of hypersensitivity to the products used in the trial\n\n          -  smokers\n\n          -  respiratory disease such as asthma and COPD\n\n          -  clinically relevant concomitant disease that may introduce a risk for the\n             subjects'safety\n\n          -  presence of kidney stones\n\n          -  dialysis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02040597", 
            "org_study_id": "CCD-05993AA1-10", 
            "secondary_id": "2013-002140-91"
        }, 
        "intervention": {
            "arm_group_label": "CHF5993 pMDI", 
            "intervention_name": "Beclometasone/Formoterol/Glycopyrrolate", 
            "intervention_type": "Drug", 
            "other_name": "CHF 5993 pMDI"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Beclomethasone", 
                "Formoterol", 
                "Glycopyrrolate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Nadarzyn", 
                        "country": "Poland", 
                        "state": "Mokra 7", 
                        "zip": "05-830"
                    }, 
                    "name": "Biovirtus Research Site"
                }, 
                "investigator": {
                    "last_name": "Kasia Jarus-Dziedzic, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lodz", 
                        "country": "Poland", 
                        "state": "ul. Kopci\u0144skiego 22", 
                        "zip": "90-153"
                    }, 
                    "name": "Medical University in Lodz"
                }, 
                "investigator": {
                    "last_name": "Piotr Kuna, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Poland"
        }, 
        "number_of_arms": "1", 
        "official_title": "Open-label, Non-randomized, Parallel-group Study to Investigate the Pharmacokinetics, Safety and Tolerability of a Single Dose of CHF 5993 pMDI in Subjects With Mild, Moderate and Severe Renal Impairment in Comparison With Matched Healthy Control Subjects.", 
        "overall_contact": {
            "email": "s.collarini@chiesi.com", 
            "last_name": "Sara Collarini, MSc", 
            "phone": "+39 0521 279 948"
        }, 
        "overall_official": [
            {
                "affiliation": "Medical University in Lodz", 
                "last_name": "Piotr Kuna, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Biovirtus", 
                "last_name": "Kasia Jarus-Dziedzic, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "AUC until the last quantifiable concentration (AUCt)", 
            "measure": "Glycopyrrolate area under the curve (AUC)", 
            "safety_issue": "No", 
            "time_frame": "over 72 h after single administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02040597"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "AUC until 72 h post dose (AUC0-72h), AUC extrapolated to infinity (AUCinf), maximum plasma concentratio (Cmax), time to maximum plasma concentration (tmax), half-life, clearance", 
                "measure": "Glycopyrrolate other Pharmacokinetic parameters in plasma", 
                "safety_issue": "No", 
                "time_frame": "Over 72 h after single administration"
            }, 
            {
                "description": "AUCt, AUC until 24 h post dose (AUC0-24h), AUCinf, Cmax, tmax, half-life, clearance", 
                "measure": "B17MP and Formoterol pharmacokinetic parameters in plasma", 
                "safety_issue": "No", 
                "time_frame": "over 24 h after single administration"
            }, 
            {
                "description": "AUCt, AUCinf, Cmax, tmax, half-life", 
                "measure": "BDP pharmacokinetic parameters in plasma", 
                "safety_issue": "No", 
                "time_frame": "over 24 h after single administration"
            }, 
            {
                "measure": "Urine Glycopyrrolate excretion (Ae)", 
                "safety_issue": "No", 
                "time_frame": "over 72 h after single administration"
            }, 
            {
                "measure": "Urine formoterol excretion (Ae)", 
                "safety_issue": "No", 
                "time_frame": "Over 24 h after single administration"
            }, 
            {
                "description": "This includes a period of 3 to 7 weeks (depending on duration of screening and follow-up periods), before and after the study drug administration", 
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "A period of 3 to 7 weeks (from screening visit to follow-up phone call)"
            }, 
            {
                "description": "systolic and diastolic blood pressure", 
                "measure": "Vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "over 24 h after single administration"
            }, 
            {
                "description": "Heart rate (HR), time interval between ECG waves Q and T corrected for heart rate with Fridericia's formula (QTcF), time interval between the onset of the ECG wave P and the start of the QRS complex (PR), time interval between the beginning of Q wave and the termination of the S wave (QRS)", 
                "measure": "Electrocardiogram (ECG) parameters", 
                "safety_issue": "Yes", 
                "time_frame": "over 24 h after single administration"
            }
        ], 
        "source": "Chiesi Farmaceutici S.p.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chiesi Farmaceutici S.p.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}